Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T13910
(Former ID: TTDI01705)
|
|||||
Target Name |
Phosphofructokinase 2 (PFK2)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Type-1/2 diabete [ICD-11: 5A10-5A11] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | INGAP peptide | Drug Info | Phase 2 | Type-1/2 diabetes | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | INGAP peptide | Drug Info | [1] |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | A Pentadecapeptide Fragment of Islet Neogenesis-Associated Protein Increases Beta-Cell Mass and Reverses Diabetes in C57BL/6J Mice. Ann Surg. 2004 November; 240(5): 875-884. | |||||
REF 2 | Liver carbohydrates metabolism: A new islet-neogenesis associated protein peptide (INGAP-PP) target. Peptides. 2018 Mar;101:44-50. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.